Ipsen SA
http://www.ipsen.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
J.P. Morgan Day 4: Setting Goals For The Year Ahead
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC.
Stockwatch: When Cash May Not Be King
Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Sterix
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation